Investigational drug · Phase 2
TB006
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Parkinson's Disease (PD).
Phase 2Last checked: Nov 19, 2026Latest source record: Apr 23, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
8
Any phase or sponsor naming "TB006"
First trial start
2025
Mar 20, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "TB006", any sponsor or status.
Conditions studied
As listed on its trial records.
- Parkinson's Disease (PD)
Approved drugs for the same conditions: Parkinson's disease · Neurology
Largest trials
Live from ClinicalTrials.gov: studies naming "TB006" as an intervention, largest first.
- Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of TB006 in Participants With Alzheimer's DiseasePivotal-lookingCompleted
TrueBinding, Inc.Industry
NCT05074498 · 154 participants · Start Oct 8, 2021 · Primary completion Oct 13, 2022
Drug: TB006; Placebo · For: Alzheimer's Disease
Sites: Garden Grove, California; San Diego, California; Delray Beach, Florida · 18 sites in all
- A Long Term Extension Study to Assess the Safety of TB006 in Participants With Alzheimer's DiseaseTerminated
TrueBinding, Inc.Industry
NCT05476783 · 119 participants · Start Sep 15, 2022 · Primary completion Nov 17, 2023
Drug: TB006 · For: Alzheimer's Disease
Sites: San Diego, California; Delray Beach, Florida; Lady Lake, Florida · 13 sites in all
- A Phase 2a Multicenter Clinical Trial of TB006 in Participants With Parkinson's DiseaseActive, not recruiting
TrueBinding, Inc.Industry
NCT06773962 · 62 participants (planned) · Start Mar 20, 2025 · Primary completion Nov 28, 2026
Drug: TB006; Placebo · For: Parkinson's Disease (PD)
Sites: Aliso Viejo, California; Palo Alto, California; Englewood, Colorado · 14 sites in all
TrueBinding, Inc.Industry
NCT04920786 · 48 participants · Start Jun 1, 2021 · Primary completion May 3, 2022
Drug: TB006 · For: Alzheimer Disease
Sites: Long Beach, California
- TB006 for Autism Spectrum DisorderRecruiting
Rossignol Medical CenterAcademic, hospital or other
NCT06500637 · 45 participants (planned) · Start Aug 3, 2024 · Primary completion Dec 31, 2026
Drug: TB006 · For: Autism Spectrum Disorder
Sites: Phoenix, Arizona; Aliso Viejo, California
TrueBinding, Inc.Industry
NCT05156827 · 0 participants · Start Jul 26, 2022 · Primary completion Dec 18, 2023
Drug: TB006; Placebo · For: Acute Ischemic Stroke
TrueBinding, Inc.Industry
NCT04801056 · 0 participants · Start Jun 1, 2021 · Primary completion Sep 1, 2021
Drug: TB006 · For: Covid19
TrueBinding, Inc.Industry
NCT05959239
Drug: TB006 · For: Alzheimer Disease
Newest research
PubMed records naming it or its code names, newest first.
- Unraveling the Immune Puzzle: Role of Immunomodulation in Alzheimer's Disease.
Ashvin, Dhapola R, Kumari S, et al. · J Neuroimmune Pharmacol 2025
Also in development for Parkinson's Disease (PD)
- buntanetapposiphenPhase 33 trials
Annovis Bio Inc. · Early Alzheimers Disease, Alzheimer's Dementia (AD), Parkinson's Disease (PD)
- TJ0113Phase 33 trials
Hangzhou PhecdaMed Co., Ltd. · Sarcopenia, Parkinson's Disease (PD), Parkinson Disease 6, Early-Onset
- SUL-238t.i.d.Phase 21 trial
GEN İlaç ve Sağlık Ürünleri A.Ş. · Parkinson's Disease (PD)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.